At #ESMO26: In a 5 year analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab versus nivolumab alone in patients with advanced melanoma, statistically significant differences in PFS and OS were seen with high baseline levels of LAG3 high CD8+ T cells associated with improved response in the combination arm
https://www.nature.com/articles/s41591-026-04756-1?utm_source=dlvr.it&utm_medium=facebook&fbclid=IwVERDUAVLvLdleHRuA2FlbQIxMABwZG9mBXNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHiQWF1RiKHlzKgvua8EWptTKdspUypwe-u4gdOUsAm16fwWj72RdthqOt7Y2_aem_-f7_JTkOyLs-_YZwqmGVqA
@NatureMedicine